Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Ken Kato, Lin Shen et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironmentsShogo Kumagai, Hiroyoshi Nishikawa, Shohei Koyama et al.|Cancer Cell|2022Cited by 828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Hiroyoshi Nishikawa, Yosuke Togashi et al.|Nature Immunology|2020Cited by 810
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Martin Schüler et al.|The Lancet Oncology|2023Cited by 195
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D. Hellmann, Toshihiko Doi, Nicoletta Bivi et al.|Clinical Cancer Research|2021Cited by 111